PPARG and breast cancer: The PTER-ITC conjugate can be considered more advantageous than existing PPARγ ligands such as rosiglitazone or pioglitazone for breast cancer treatment, as PTER-ITC causes more pronounced cell death at a much lower dose than other ligands [50]–[52].